局部进展期结肠癌病人的新辅助治疗

doi:10.16139/j.1007-9610.2022.03.017

摘要/Abstract

摘要：

局部进展期结肠癌（locally advanced colon cancer, LACC）的新辅助治疗仍不明确。为进一步提高LACC病人的生存率,本文总结新辅助化疗、新辅助化疗联合靶向治疗以及放、化疗联合治疗LACC,重点是安全性和有效性。

关键词: 结肠癌, 局部进展期, 新辅助治疗

Abstract:

It is still unclear about neoadjuvant therapy in patients with locally advanced colon cancer (LACC). This review summarized neoadjuvant chemotherapy, neoadjuvant chemotherapy combined with targeted therapy and combined radio-chemotherapy for the patients with LACC to increase the survival of patients focusing on the efficacy and safety of neoadjuvant therapy.

Key words: Colon cancer, Locally advanced stage, Neoadjuvant therapy

中图分类号:

R735.35

许梓枫综述, 宗雅萍, 陆爱国审校. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(03): 266-270.

XU Zifeng, ZONG Yaping, LU Aiguo. Neoadjuvant therapy in patients with locally advanced colon cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 266-270.

参考文献 40

[1]	Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer[J]. Int J Mol Sci, 2017, 18(1):197. doi: 10.3390/ijms18010197 URL
[2]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[3]	Reima H, Soplepmann J, Elme A, et al. Changes in the quality of care of colorectal cancer in Estonia: a population-based high-resolution study[J]. BMJ Open, 2020, 10(10):e035556. doi: 10.1136/bmjopen-2019-035556 URL
[4]	De Haas-Kock DF, Buijsen J, Pijls-Johannesma M, et al. Concomitant hyperthermia and radiation therapy for trea-ting locally advanced rectal cancer[J]. Cochrane Database Syst Rev, 2009, 3:CD006269.
[5]	Huang CM, Huang MY, Ma CJ, et al. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer[J]. Radiat Oncol, 2017, 12(1):48. doi: 10.1186/s13014-017-0790-3 URL
[6]	Dehal A, Graff-Baker AN, Vuong B, et al. Neoadjuvant chemotherapy improves survival in patients with clinical T_4b colon cancer[J]. J Gastrointest Surg, 2018, 22(2):242-249. doi: 10.1007/s11605-017-3566-z URL
[7]	Karoui M, Rullier A, Luciani A, et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with cetuximab versus immediate surgery for high-risk stage Ⅱ and Ⅲ colon cancers: a multicenter randomised controlled phase Ⅱ trial--the PRODIGE 22--ECKINOXE trial[J]. BMC Cancer, 2015, 15:511. doi: 10.1186/s12885-015-1507-3 pmid: 26156156
[8]	Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomized controlled trial[J]. Lancet Oncol, 2012, 13(11):1152-1160. doi: 10.1016/S1470-2045(12)70348-0 pmid: 23017669
[9]	Liu F, Tong T, Huang D, et al. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomized controlled phase Ⅲ trial[J]. BMJ Open, 2019, 9(1):e017637. doi: 10.1136/bmjopen-2017-017637 URL
[10]	Dehal AN, Graff-Baker AN, Vuong B, et al. Correlation between clinical and pathologic staging in colon cancer: implications for neoadjuvant treatment[J]. J Gastrointest Surg, 2018, 22(10):1764-1771. doi: 10.1007/s11605-018-3777-y URL
[11]	Liu F, Yang L, Wu Y, et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase Ⅱ trial[J]. Chin J Cancer Res, 2016, 28(6):589-597. doi: 10.21147/j.issn.1000-9604.2016.06.05 URL
[12]	Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. a phase Ⅱ trial[J]. Acta Oncol, 2015, 54(10):1747-1753. doi: 10.3109/0284186X.2015.1037007 pmid: 25920359
[13]	Wu C. Systemic therapy for colon cancer[J]. Surg Oncol Clin N Am, 2018, 27(2):235-242. doi: 10.1016/j.soc.2017.11.001 URL
[14]	Chang H, Yu X, Xiao WW, et al. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study[J]. Onco Targets Ther, 2018, 11:409-418. doi: 10.2147/OTT.S150367 URL
[15]	Tomizawa K, Miura Y, Fukui Y, et al. Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: a case report[J]. Int J Surg Case Rep, 2017, 31:128-131. doi: 10.1016/j.ijscr.2017.01.027 URL
[16]	Arredondo J, Baixauli J, Pastor C, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery[J]. Clin Transl Oncol, 2017, 19(3):379-385. doi: 10.1007/s12094-016-1539-4 pmid: 27496023
[17]	Hawkins AT, Ford MM, Geiger TM, et al. Neoadjuvant radiation for clinical T₄ colon cancer: a potential improvement to overall survival[J]. Surgery, 2019, 165(2):469-475. doi: 10.1016/j.surg.2018.06.015 URL
[18]	Sekiya S, Imamura K, Takeuchi S, et al. Pathological complete response of locally advanced colon cancer after preoperative radiotherapy: a case report and narrative review of the literature[J]. Surg Case Rep, 201815, 4(1):58.
[19]	Reibetanz J, Germer CT. Neoadjuvant chemotherapy for locally advanced colon cancer: initial results of the FOxTROT study[J]. Chirurg, 2013-10-13. [online ahead of print]
[20]	Pellino G, Warren O, Mills S, et al. Comparison of Wes-tern and Asian guidelines concerning the management of colon cancer[J]. Dis Colon Rectum, 2018, 61(2):250-259. doi: 10.1097/DCR.0000000000001012 URL
[21]	李英杰, 武云龙, 崔健, 等. cT₄N+期结肠癌新辅助化疗后外科治疗的效果和安全性[J]. 中华肿瘤杂志, 2019, 41(6):454-459.
[22]	彭俊杰, 朱骥, 刘方奇, 等. 中国局部进展期直肠癌诊疗专家共识[J]. 中国癌症杂志, 2017, 27(1):41-80.
[23]	Meyers BM, Cosby R, Quereshy F, et al. Adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer follo-wing complete resection: a cancer care ontario syste-matic review[J]. Clin Oncol, 2017, 29(7):459-465. doi: 10.1016/j.clon.2017.03.001 URL
[24]	Zhou H, Song Y, Jiang J, et al. A pilot phase Ⅱ study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer[J]. Chin J Cancer Res, 2016, 28(6):598-605. doi: 10.21147/j.issn.1000-9604.2016.06.06 URL
[25]	Serrano PE, Carter DN, Li C, et al. Adjuvant chemothe-rapy with or without biologics including antiangiogenics and monoclonal antibodies targeting EGFR and EpCAM in colorectal cancer: a systematic review and meta-analysis[J]. J Surg Res, 2019, 239:14-21. doi: S0022-4804(19)30037-X pmid: 30782542
[26]	Wiegering A, Kunz M, Hussein M, et al. Diagnostic value of preoperative CT scan to stratify colon cancer for neoadjuvant therapy[J]. Int J Colorectal Dis, 2015, 30(8):1067-1073. doi: 10.1007/s00384-015-2265-z pmid: 25997602
[27]	Venigalla S, Chowdhry AK, Wojcieszynski AP, et al. Comparative effectiveness of neoadjuvant chemoradiation versus upfront surgery in the management of recto-sigmoid junction cancer[J]. Clin Colorectal Cancer, 2018, 17(3):e557-e568.
[28]	Cheong CK, Nistala KRY, Ng CH, et al. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review[J]. J Gastrointest Oncol, 2020, 11(5):847-857. doi: 10.21037/jgo-20-220 pmid: 33209481
[29]	杨晓东, 刘弋. 基于循证医学的结肠癌新辅助化疗[J]. 中华胃肠外科杂志, 2014, 17(11):1151-1155.
[30]	Ahmed S, Johnson K, Ahmed O, et al. Advances in the management of colorectal cancer: from biology to treatment[J]. Int J Colorectal Dis, 2014, 29(9):1031-1042. doi: 10.1007/s00384-014-1928-5 URL
[31]	Ceelen W, van Nieuwenhove Y, Putte DV, et al. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis[J]. Ann Surg Oncol, 2014, 21(9):3023-3028. doi: 10.1245/s10434-014-3713-7 pmid: 24756812
[32]	Huang L, Li TJ, Zhang JW, et al. Neoadjuvant chemothe-rapy followed by surgery versus surgery alone for colorec-tal cancer: meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2014, 93(28):e231. doi: 10.1097/MD.0000000000000231 URL
[33]	Krishnamurty DM, Hawkins AT, Wells KO, et al. Neoadjuvant radiation therapy in locally advanced colon cancer: a cohort analysis[J]. J Gastrointest Surg, 2018, 22(5):906-912. doi: 10.1007/s11605-018-3676-2 pmid: 29427227
[34]	Klaver CE, Gietelink L, Bemelman WA, et al. Dutch surgical colorectal audit group. locally advanced colon cancer: evaluation of current clinical practice and treatment outcomes at the population level[J]. J Natl Compr Canc Netw, 2017, 15(2):181-190. doi: 10.6004/jnccn.2017.0019 URL
[35]	Musiienko AM, Alzahrani S, Simpson JAD, et al. Pre-operative chemoradiation for an ascending colon tumour: novel approach to achieve a complete resection[J]. ANZ J Surg, 2018, 88(4):E342-E344.
[36]	Nishikawa T, Ishihara S, Emoto S, et al. Multivisceral resections for locally advanced colorectal cancer after preoperative treatment[J]. Mol Clin Oncol, 2018, 8(3):493-498. doi: 10.3892/mco.2018.1559 pmid: 29564129
[37]	Qiu B, Ding PR, Cai L, et al. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer[J]. Chin J Cancer, 2016, 35(1):65. doi: 10.1186/s40880-016-0126-y pmid: 27389519
[38]	Hallet J, Zih FS, Lemke M, et al. Neo-adjuvant chemoradiotherapy and multivisceral resection to optimize R0 resection of locally recurrent adherent colon cancer[J]. Eur J Surg Oncol, 2014, 40(6):706-712. doi: 10.1016/j.ejso.2014.01.009 pmid: 24534363
[39]	Zhou J, Guo Z, Yu W, et al. Clinical evaluation of pre-operative radiotherapy combined with FOLFOX chemothe-rapy on patients with locally advanced colon cancer[J]. Am Surg, 2019, 85(4):313-320.
[40]	Choi JH, Kim JH, Moon W, et al. Is it possible to successfully treat locally advanced colon cancer using pre-operative chemoradiotherapy?[J]. Clin Endosc, 2019, 52(2):191-195. doi: 10.5946/ce.2018.088 pmid: 30408944